Bedaquiline D9
| Product Name | Bedaquiline D9 |
|---|---|
| Alternate Names | Bedaquiline Stable Isotopes, Stable Isotopes of Bedaquiline |
| CAT No. | CS-P-00667 |
| CAS No. | 843663-66-1 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Bedaquiline |
| Smileys | O[C@@](CCN(C([2H])([2H])[2H])C([2H])([2H])[2H])(C1=CC=CC2=C1C=CC=C2)[C@@H](C3=CC=CC=C3)C4=CC(C=C(Br)C=C5)=C5N=C4OC([2H])([2H])[2H] |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Bedaquiline D9 is a deuterated form of Bedaquiline, an anti-tuberculosis drug that was first approved by the US FDA in 2012. It is used to treat pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults as part of a combination therapy. MDR-TB is a form of tuberculosis that is resistant to at least two of the most powerful anti-TB drugs, making it difficult to treat. Bedaquiline D9 works by inhibiting the activity of the enzyme ATP synthase, which is essential for the survival of the bacteria that cause TB.
Bedaquiline D9 is administered orally, with a recommended dose of 400 mg once daily for the first two weeks, followed by a reduced dose of 200 mg three times a week for the next 22 weeks. It is important to take the medication as directed by a healthcare professional, and to complete the full course of treatment, even if symptoms improve.
Chemically, Bedaquiline D9 is a deuterated analog of Bedaquiline, meaning that some of the hydrogen atoms in the molecule have been replaced with deuterium atoms. This modification can improve the drug's pharmacokinetic properties, such as its absorption, distribution, and elimination from the body. Deuterated drugs are becoming increasingly popular in drug development due to their potential to improve drug efficacy and safety.
Get an Instant Quote
Related Compounds
N-desmethyl Bedaquiline-13CD3 | Bedaquiline D6 | N-Desmethyl-bedaquiline D6 |